Sign In
Buy IVVD
$1.10
-0.0400 (-3.51%)
At Close: Jun 03, 2026
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
04:15pm, Wednesday, 26'th Mar 2025
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focuse
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
10:25am, Thursday, 20'th Mar 2025
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago.
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
08:01am, Thursday, 20'th Mar 2025
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced fi
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
07:05am, Wednesday, 05'th Mar 2025
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart) aga
5 Stocks That More Than Doubled Halfway Through Q1
10:40am, Monday, 24'th Feb 2025
We highlight five stocks from different sectors that more than doubled halfway through the first quarter.
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients
09:20am, Monday, 24'th Feb 2025
On Monday, the FDA declined Invivyd, Inc.'s IVVD request to expand the existing emergency use authorization (EUA) for pre-exposure prophylaxis of COVID-19 EUA for Pemgarda (pemivibart) for mild-to-m
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Invivyd's request to expand the existing emergency use authorization (EUA) for pre-exposure prophyla
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
07:00am, Monday, 10'th Feb 2025
WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th An
Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
09:30am, Wednesday, 05'th Feb 2025
WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a strategic partnership with renowned professional football coach Jim Harbaugh to raise awareness about t
I See The Bull Case For Invivyd, But I'm Not Married To It
03:55pm, Tuesday, 04'th Feb 2025
Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue i
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced pre
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
07:01am, Friday, 10'th Jan 2025
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced tha
Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript
02:15pm, Thursday, 14'th Nov 2024
Start Time: 08:30 January 1, 0000 9:18 AM ET Invivyd, Inc. (NASDAQ:IVVD ) Q3 2024 Earnings Conference Call November 14, 2024, 08:30 AM ET Company Participants Marc Elia - Chairperson, Board of Directo
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
09:20am, Thursday, 14'th Nov 2024
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.36 per share a year ago.
